Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MK-8189 by Merck for Schizophrenia: Likelihood of Approval
MK-8189 is under clinical development by Merck and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs...
Human papillomavirus (virus like particle, 9-valent) vaccine by Merck for Human Papillomavirus Infections: Likelihood of Approval
Human papillomavirus (virus like particle, 9-valent) vaccine is under clinical development by Merck and currently in Phase II for Human...
Vicriviroc by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
Vicriviroc is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Ulevostinag by Merck for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Ulevostinag is under clinical development by Merck and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...
Bintrafusp alfa by Merck for Metastatic Colorectal Cancer: Likelihood of Approval
Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Pembrolizumab by Merck for Gliosarcoma: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs...
Pembrolizumab by Merck for Uterine Cancer: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...
Pembrolizumab by Merck for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...
Pembrolizumab by Merck for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Avelumab by Merck for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Avelumab is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Pembrolizumab by Merck for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)....
Letermovir by Merck for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Letermovir is under clinical development by Merck and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According...
Pembrolizumab by Merck for Kaposi Sarcoma: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I...
Pembrolizumab by Merck for Bladder Cancer: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III...
Pembrolizumab by Merck for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Pembrolizumab is under clinical development by Merck and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
Nedisertib by Merck for Solid Tumor: Likelihood of Approval
Nedisertib is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Merck's Quavonlimab?
Quavonlimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Merck's Vibostolimab?
Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Merck's Nemtabrutinib?
Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Chronic Lymphocytic Leukemia (CLL). According...
Risk adjusted net present value: What is the current valuation of Merck's Favezelimab?
Favezelimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...